Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$35.39 -1.7%	$40.18	$26.20 ▼ $63.50	$1.63B	1.43	676,257 shs	622,255 shs
CMPS COMPASS Pathways	$4.39 +1.9%	$4.01	$2.25 ▼ $8.54	$421.18M	2.17	2.16 million shs	840,147 shs
SPRY ARS Pharmaceuticals	$17.50 -0.8%	$16.71	$9.67 ▼ $18.90	$1.72B	0.9	1.19 million shs	715,574 shs
SRPT Sarepta Therapeutics	$18.23 +1.5%	$21.73	$10.41 ▼ $144.22	$1.78B	0.46	22.70 million shs	10.38 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	-6.25%	-8.24%	-5.10%	-13.41%
CMPS COMPASS Pathways	0.00%	+1.15%	+18.01%	+15.83%	-35.72%
SPRY ARS Pharmaceuticals	0.00%	+1.86%	-2.67%	+30.21%	+82.96%
SRPT Sarepta Therapeutics	0.00%	+14.58%	-4.40%	-49.74%	-86.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APGE Apogee Therapeutics	2.6498 of 5 stars	3.5	0.0	0.0	4.0	4.2	0.0
CMPS COMPASS Pathways	2.8085 of 5 stars	3.4	4.0	0.0	2.9	0.8	0.6
SPRY ARS Pharmaceuticals	3.3794 of 5 stars	3.6	2.0	0.0	3.4	4.2	0.6
SRPT Sarepta Therapeutics	4.6156 of 5 stars	4.1	2.0	4.2	3.0	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	3.00	Buy	$99.00	179.74% Upside
CMPS COMPASS Pathways	2.86	Moderate Buy	$16.29	270.97% Upside
SPRY ARS Pharmaceuticals	3.17	Buy	$31.00	77.14% Upside
SRPT Sarepta Therapeutics	2.10	Hold	$44.17	142.27% Upside

Current Analyst Ratings Breakdown

Latest CMPS, APGE, SPRY, and SRPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	SRPT Sarepta Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$19.00
8/7/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$48.00 ➝ $50.00
8/4/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$45.00 ➝ $40.00
8/1/2025	CMPS COMPASS Pathways	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
7/29/2025	SRPT Sarepta Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$22.00
7/29/2025	SRPT Sarepta Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
7/29/2025	SRPT Sarepta Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Perform ➝ Market Perform	$25.00 ➝ $50.00
7/29/2025	SRPT Sarepta Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $20.00
7/29/2025	SRPT Sarepta Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$15.00
7/29/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell
7/29/2025	SRPT Sarepta Therapeutics	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$13.00

(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$15.92 per share	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$1.69 per share	N/A
SPRY ARS Pharmaceuticals	$89.15M	19.28	$0.01 per share	2,066.53	$2.64 per share	6.63
SRPT Sarepta Therapeutics	$1.90B	0.94	$2.44 per share	7.48	$13.89 per share	1.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$182.15M	-$3.60	N/A	N/A	N/A	N/A	-28.35%	-26.98%	8/11/2025 (Estimated)
CMPS COMPASS Pathways	-$155.12M	-$1.84	N/A	N/A	N/A	N/A	-87.89%	-57.77%	N/A
SPRY ARS Pharmaceuticals	$8M	-$0.16	N/A	N/A	N/A	-16.11%	-6.94%	-5.60%	8/13/2025 (Estimated)
SRPT Sarepta Therapeutics	$235.24M	-$0.87	N/A	1.67	N/A	-2.34%	-1.03%	-0.37%	N/A

Latest CMPS, APGE, SPRY, and SRPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	SPRY ARS Pharmaceuticals	-$0.42	N/A	N/A	N/A	$12.92 million	N/A
8/11/2025	Q2 2025	APGE Apogee Therapeutics	-$1.08	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	SRPT Sarepta Therapeutics	$0.89	$2.02	+$1.13	$1.89	$530.66 million	$611.09 million
7/31/2025	Q2 2025	CMPS COMPASS Pathways	-$0.37	-$0.38	-$0.01	-$0.41	N/A	N/A
5/14/2025	Q1 2025	SPRY ARS Pharmaceuticals	-$0.35	-$0.35	N/A	-$0.35	$7.48 million	$7.97 million
5/12/2025	Q1 2025	APGE Apogee Therapeutics	-$1.19	-$0.95	+$0.24	-$0.95	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	15.82	15.82
CMPS COMPASS Pathways	0.16	8.82	8.82
SPRY ARS Pharmaceuticals	0.30	11.00	10.74
SRPT Sarepta Therapeutics	0.84	2.89	2.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
CMPS COMPASS Pathways	46.19%
SPRY ARS Pharmaceuticals	68.16%
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	42.77%
CMPS COMPASS Pathways	3.93%
SPRY ARS Pharmaceuticals	33.50%
SRPT Sarepta Therapeutics	7.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	46.05 million	26.35 million	Optionable
CMPS COMPASS Pathways	120	95.94 million	92.17 million	Optionable
SPRY ARS Pharmaceuticals	90	98.21 million	65.31 million	Optionable
SRPT Sarepta Therapeutics	1,372	97.71 million	90.19 million	Optionable

CMPS, APGE, SPRY, and SRPT Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT

August 9 at 10:43 AM | globenewswire.com

SRPT NEWS: Did Sarepta Therapeutics Mislead Investors? Contact BFA Law by August 25 Class Action Deadline (NASDAQ:SRPT)

August 9 at 7:36 AM | globenewswire.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by New Age Alpha Advisors LLC

August 9 at 4:27 AM | marketbeat.com

SRPT INVESTOR NOTICE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

August 8 at 9:40 PM | prnewswire.com

BMO Capital Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)

August 8 at 8:03 PM | theglobeandmail.com

Shareholders that lost money on Sarepta Therapeutics, Inc.(SRPT) should contact Levi & Korsinsky about pending Class Action - SRPT

August 8 at 4:04 PM | globenewswire.com

SRPT Deadline: SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit

August 8 at 3:22 PM | prnewswire.com

Goldman Sachs Sticks to Their Hold Rating for Sarepta Therapeutics (SRPT)

August 8 at 3:02 PM | theglobeandmail.com

The Goldman Sachs Group Issues Positive Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price

August 8 at 2:29 PM | marketbeat.com

Wells Fargo & Company Issues Positive Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price

August 8 at 11:52 AM | marketbeat.com

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

August 8 at 10:50 AM | prnewswire.com

Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up on Strong Earnings

August 8 at 10:21 AM | marketbeat.com

Sarepta Therapeutics (SRPT) Declines Again On EMA Recommendation to Refuse ELEVIDYS Marketing Authorization, Securities Class Action Pending – Hagens Berman

August 8 at 9:05 AM | globenewswire.com

August 25, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SRPT

August 8 at 8:45 AM | prnewswire.com

Cautious Outlook for Sarepta Therapeutics Amid Uncertain Demand and Regulatory Challenges

August 8 at 5:44 AM | tipranks.com

SRPT DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SRPT

August 7 at 6:59 PM | globenewswire.com

Sarepta Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 25, 2025 Deadline to file Lead Plaintiff Motion.

August 7 at 5:01 PM | globenewswire.com

Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) - August 25, 2025 Deadline to Join – Contact The Gross Law Firm

August 7 at 4:32 PM | globenewswire.com

Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries

August 7 at 10:32 AM | zacks.com

SRPT SHAREHOLDERS: Sarepta Therapeutics Stock Drop Triggers Securities Fraud Class Action -- ...

August 7 at 9:22 AM | gurufocus.com

SRPT SHAREHOLDERS: Sarepta Therapeutics Stock Drop Triggers Securities Fraud Class Action – Contact BFA Law by August 25 if You Lost Money (NASDAQ:SRPT)

August 7 at 8:18 AM | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS, APGE, SPRY, and SRPT Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$35.39 -0.61 (-1.69%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$36.38 +0.99 (+2.81%)

As of 08/8/2025 06:31 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

COMPASS Pathways NASDAQ:CMPS

$4.39 +0.08 (+1.86%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$4.39 +0.00 (+0.11%)

As of 08/8/2025 07:47 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

ARS Pharmaceuticals NASDAQ:SPRY

$17.50 -0.15 (-0.85%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$17.50 0.00 (0.00%)

As of 08/8/2025 07:08 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Sarepta Therapeutics NASDAQ:SRPT

$18.23 +0.27 (+1.50%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$18.20 -0.03 (-0.16%)

As of 08/8/2025 07:59 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time